Charles River Laboratories Announces Third-Quarter 2012 Results from Continuing Operations

– Third-Quarter GAAP Earnings per Share of $0.46
and Non-GAAP Earnings per Share of $0.65 –

WILMINGTON, Mass.--(BUSINESS WIRE)--October 30, 2012--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2012. For the quarter, net sales from continuing operations were $278.7 million, an increase of 0.4% from $277.6 million in the third quarter of 2011. Excluding foreign currency translation, which reduced reported sales by 3.2%, third-quarter 2012 sales increased by 3.6%. On a segment basis, sales increased in the Preclinical Services (PCS) segment, but declined in the Research Models and Services (RMS) segment due primarily to foreign currency translation.

On a GAAP basis, net income from continuing operations for the third quarter of 2012 was $22.4 million, or $0.46 per diluted share, compared to $18.9 million, or $0.37 per diluted share, for the third quarter of 2011.

On a non-GAAP basis, net income from continuing operations was $31.2 million for the third quarter of 2012, an increase of 8.7% from $28.7 million for the same period in 2011. Third-quarter 2012 diluted earnings per share on a non-GAAP basis were $0.65, an increase of 14.0% compared to $0.57 per share in the third quarter of 2011. Non-GAAP earnings per share benefited primarily from an improvement in the PCS operating margin and stock repurchases.

James C. Foster, Chairman, President and Chief Executive Officer, said, “We are experiencing a pivotal moment in time when global biopharmaceutical companies are reinventing the drug discovery and development model. As our clients grapple with the logistics of how and what to outsource, we are extremely well positioned to assist them in the decision-making process, and to be the strategic partner of choice when they do outsource. We have prepared ourselves for this moment by focusing on scientific excellence, operating efficiency, and information technology platforms, and are utilizing our broad, early-stage portfolio and all of our capabilities in innovative working arrangements that suit our clients’ individual needs.”

“We believe this approach has enabled us to take market share in a highly competitive environment, such as our recently announced partnership with AstraZeneca. We are enhancing our position with strategic targeted acquisitions which expand our capabilities, such as Accugenix, or our global reach, as with our planned majority acquisition of Vital River. This furthers our goal to increase the value proposition we can offer to clients, as a premier provider of essential early-stage drug research products and services.”

The Company reports results from continuing operations, which excludes results of the Phase I clinical business that was divested in 2011. The Phase I business is reported as a discontinued operation.

Net sales for the RMS segment were $166.5 million in the third quarter of 2012, a decrease of 2.9% from $171.5 million in the third quarter of 2011. Excluding foreign exchange, which reduced reported sales by 4.1%, RMS sales increased by 1.2% due to continued strong sales growth for Other Products, which includes the Endotoxin and Microbial Detection (formerly In Vitro) and Avian Vaccine businesses. This was largely offset by softness in the research models business, particularly for large models.

In the third quarter of 2012, the RMS segment’s GAAP operating margin was 26.1% compared to 28.3% for the third quarter of 2011. On a non-GAAP basis, the operating margin increased to 29.3% from 29.0% in the third quarter of 2011. The non-GAAP operating margin improvement was primarily attributable to leverage from higher sales of Other Products, as well as the benefits of ongoing efficiency initiatives.

Third-quarter 2012 net sales from continuing operations for the PCS segment were $112.2 million, an increase of 5.7% from $106.1 million in the third quarter of 2011. Foreign currency translation reduced reported sales by 1.8%. Excluding foreign exchange, constant-currency sales growth of 7.5% was primarily driven by increased demand for both regulated safety assessment and non-GLP discovery services.

In the third quarter of 2012, the PCS segment’s GAAP operating margin increased to 9.8% from 3.5% in the third quarter of 2011. On a non-GAAP basis, the operating margin increased to 13.0% from 9.3% in the third quarter of 2011. The non-GAAP operating margin increase was primarily attributable to improved capacity utilization as a result of the higher sales volume.

During the third quarter of 2012, the Company repurchased approximately 416,000 shares for $15.0 million. As of September 29, 2012, Charles River had $73.5 million remaining on its $750 million stock repurchase authorization.

For the first nine months of 2012, net sales decreased by 0.3% to $849.4 million from $851.7 million in the same period in 2011. Foreign currency translation reduced reported sales by 2.4%.

On a GAAP basis, net income from continuing operations for the first nine months of 2012 was $79.4 million, or $1.63 per diluted share, compared to $88.4 million, or $1.69 per diluted share, for the same period in 2011.

On a non-GAAP basis, net income from continuing operations for the first nine months of 2012 was $101.5 million, or $2.09 per diluted share, compared to $97.8 million, or $1.87 per diluted share, for the same period in 2011.

For the first nine months of 2012, RMS net sales were $523.2 million, essentially unchanged from $523.0 million for the same period in 2011. Foreign currency translation reduced reported sales by 2.9%. On a GAAP basis, the RMS segment operating margin was 30.3% for the first nine months of 2012, compared to 29.8% for the prior-year period. On a non-GAAP basis, the operating margin was 31.9% for the first nine months of 2012, compared to 31.0% for the same period in 2011.

For the first nine months of 2012, PCS net sales were $326.1 million, a decrease of 0.8% from $328.7 million in the same period in 2011. Foreign currency translation reduced reported sales by 1.6%. On a GAAP basis, the PCS segment operating margin was 8.0% for the first nine months of 2012, compared to 6.3% for the prior-year period. On a non-GAAP basis, the operating margin was 11.7% for the first nine months of 2012, compared to 12.5% for the same period in 2011.

Items excluded from non-GAAP results in the third quarter of 2012 and 2011 were as follows:

^{(1) In the third quarter of 2012, items were related primarily to
an asset impairment associated with the consolidation of certain RMS
Europe operations, partially offset by a gain on the sale of real estate
related to RMS Canada}

Items excluded from non-GAAP results in the first nine months of 2012 and 2011 were as follows:

($ in millions)	YTD12	YTD11
Amortization of intangible assets	$13.4	$16.5
Severance related to cost-savings actions	1.9	1.3
Impairment and other charges (1)	2.9	0.8
Adjustment of contingent consideration related to acquisitions	--	(1.2)
Operating losses for PCS China, Massachusetts and Arkansas	3.0	8.3
Costs associated with evaluation of acquisitions	1.6	0.2
Gain on settlement of life insurance policy	--	(7.7)
Write-off of deferred financing costs related to amended credit agreement	--	1.5
Loss on the sale of auction rate securities	0.7	--
Fees and tax costs associated with corporate subsidiary restructuring	--	1.5
Convertible debt accounting	10.9	10.2
Tax benefit related to disposition of Phase I clinical business	--	(11.1)

^{(1) In the first nine months of 2012, items were related primarily
to an asset impairment associated with the consolidation of certain RMS
Europe operations, partially offset by a gain on the sale of real estate
related to RMS Canada. In the first nine months of 2011, these items
were related primarily to an asset impairment associated with the
Company’s RMS large model operations and a gain related to the
disposition of its RMS Discovery Research Services facility in Michigan,
as well as exiting a defined benefit plan in RMS Japan.}

The Company is updating its forward-looking guidance based on continuing operations for 2012. Foreign currency translation is still expected to reduce reported sales by approximately 2% for the year. The Company has revised its full year, constant-currency sales guidance to reflect slightly lower-than-expected growth in the RMS segment. The Company has narrowed both its GAAP and non-GAAP earnings per share guidance for 2012 to reflect the strong year-to-date performance.

The updated guidance assumes that total net sales for the fourth quarter improve slightly on a sequential basis due to the RMS segment, which includes a full-quarter benefit from the Accugenix acquisition. The non-GAAP operating margin is expected to decline moderately from the third-quarter level due to seasonal trends in both segments. In addition, the year-over-year comparison will be affected by the inclusion of a 53^rd week last year, which is expected to negatively impact the sales growth rate in the fourth quarter of 2012.

^{(1) These costs relate primarily to the Company’s PCS facility in
Massachusetts.}

^{(2) Other items primarily include: costs associated with the
evaluation of acquisitions; a loss on the sale of auction rate
securities; and a gain on the sale of real estate related to RMS Canada.}

Charles River Laboratories has scheduled a live webcast on Wednesday, October 31, at 8:30 a.m. ET to discuss matters relating to this press release. To participate, please go to ir.criver.com and select the webcast link. You can also find the associated slide presentation and reconciliations of non-GAAP financial measures to comparable GAAP financial measures on the website.

This press release contains non-GAAP financial measures, such as non-GAAP earnings per diluted share, which exclude the amortization of intangible assets and other charges related to our acquisitions, expenses associated with evaluating acquisitions, charges and operating losses attributable to our businesses we plan to close or divest, severance costs associated with our cost-savings actions, taxes associated with the disposition of our Phase I clinical business, the gain on the settlement of a life insurance policy, fees and tax costs associated with corporate subsidiary restructuring, and the additional interest recorded as a result of the adoption in 2009 of an accounting standard related to our convertible debt accounting which increased interest and depreciation expense. We exclude these items from the non-GAAP financial measures because they are outside our normal operations. This press release also refers to our sales in both a GAAP and non-GAAP (constant currency) basis. There are limitations in using non-GAAP financial measures, as they are not prepared in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges, and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions (and in certain cases, the evaluation of such acquisitions, whether or not ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities, such as business acquisitions, happen infrequently and the underlying costs associated with such activities do not recur on a regular basis. Presenting sales on a constant currency basis allows investors to measure our organic sales growth net of foreign currency exchange fluctuations more clearly. Non-GAAP results also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered superior to or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Reconciliations of the non-GAAP financial measures used in this press release to the most directly comparable GAAP financial measures are set forth in the text of this press release, and can also be found on the Company’s website at ir.criver.com.

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “will,” “may,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding our projected 2012 financial performance including sales, earnings per share, and the expected impact of foreign exchange rates; the future demand for drug discovery and development products and services; including our expectations for revenue trends for 2012; the development and performance of our services and products, including the impact this can have on our clients’ drug development models; market and industry conditions including the outsourcing of these services and present spending trends by our customers; the impact of specific actions intended to more accurately align our infrastructure to the current operating environment, and to improve overall operating efficiencies and profitability; and Charles River’s future performance as delineated in our forward-looking guidance, and particularly our expectations with respect to sales and foreign exchange impact. Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to: the ability to successfully integrate businesses we acquire; the ability to execute our cost-savings actions on an effective and timely basis (including divestitures and site closures); the timing and magnitude of our share repurchases; negative trends in research and development spending, negative trends in the level of outsourced services, or other cost reduction actions by our customers; the ability to convert backlog to sales; special interest groups; contaminations; industry trends; new displacement technologies; USDA and FDA regulations; changes in law; continued availability of products and supplies; loss of key personnel; interest rate and foreign currency exchange rate fluctuations; changes in tax regulation and laws; changes in generally accepted accounting principles; and any changes in business, political, or economic conditions due to the threat of future terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas. A further description of these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form 10-K as filed on February 27, 2012, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law.

Accelerating Drug Development. Exactly. Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.



CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(dollars in thousands, except for per share data)

	Three Months Ended						Nine Months Ended
	September 29, 2012			September 24, 2011			September 29, 2012			September 24, 2011

Total net sales	$	278,686		$	277,579		$	849,390		$	851,685
Cost of products sold and services provided		185,427			184,863			548,334			550,011
Gross margin		93,259			92,716			301,056			301,674
Selling, general and administrative		51,047			50,345			156,924			152,561
Amortization of intangibles		4,530			5,277			13,436			16,454
Operating income		37,682			37,094			130,696			132,659
Interest income (expense)		(8,395	)		(11,806	)		(24,573	)		(31,559	)
Other income (expense)		(892	)		(747	)		(2,582	)		(1,092	)
Income from continuing operations before income taxes		28,395			24,541			103,541			100,008
Provision (benefit) for income taxes		6,011			5,630			24,140			11,564
Income from continuing operations, net of tax		22,384			18,911			79,401			88,444
Discontinued operations, net of tax		(182	)		(18	)		(63	)		(5,695	)
Net income		22,202			18,893			79,338			82,749
Noncontrolling interests		(230	)		(95	)		(459	)		(298	)
Net income attributable to common shareowners	$	21,972		$	18,798		$	78,879		$	82,451

Earnings per common share
Basic:
Continuing operations	$	0.47		$	0.38		$	1.64		$	1.71
Discontinued operations	$	-		$	-		$	-		$	(0.11	)
Net	$	0.46		$	0.38		$	1.64		$	1.60
Diluted:
Continuing operations	$	0.46		$	0.37		$	1.63		$	1.69
Discontinued operations	$	-		$	-		$	-		$	(0.11	)
Net	$	0.46		$	0.37		$	1.63		$	1.58

Weighted average number of common shares outstanding
Basic		47,625,806			50,084,850			48,028,602			51,671,559
Diluted		48,108,614			50,533,747			48,476,146			52,238,427



CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(dollars in thousands)

	September 29, 2012		December 31, 2011
Assets
Current assets
Cash and cash equivalents	$	83,224	$	68,905
Trade receivables, net		215,621		184,810
Inventories		93,718		92,969
Other current assets		65,243		79,052
Current assets of discontinued businesses		109		107
Total current assets		457,915		425,843
Property, plant and equipment, net		724,699		738,030
Goodwill, net		207,420		197,561
Other intangibles, net		89,777		93,437
Deferred tax asset		45,917		44,804
Other assets		40,987		57,659
Long-term assets of discontinued businesses		903		986
Total assets	$	1,567,618	$	1,558,320

Liabilities and Equity
Current liabilities
Current portion of long-term debt & capital leases	$	125,603	$	14,758
Accounts payable		27,744		34,332
Accrued compensation		48,771		41,602
Deferred revenue		57,833		56,530
Accrued liabilities		49,655		54,377
Other current liabilities		14,539		14,033
Current liabilities of discontinued businesses		1,092		1,165
Total current liabilities		325,237		216,797
Long-term debt and capital leases		543,143		703,187
Other long-term liabilities		96,975		108,451
Long-term liabilities of discontinued businesses		2,311		2,522
Total liabilities		967,666		1,030,957
Non-controlling interests		2,239		1,780
Total equity		599,952		527,363
Total liabilities and equity	$	1,567,618	$	1,558,320



CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED)
(dollars in thousands)

	Three Months Ended						Nine Months Ended
	September 29, 2012			September 24, 2011			September 29, 2012			September 24, 2011
Research Models and Services
Net sales	$	166,484		$	171,471		$	523,247		$	523,005
Gross margin		65,902			70,514			224,364			222,660
Gross margin as a % of net sales		39.6	%		41.1	%		42.9	%		42.6	%
Operating income		43,389			48,534			158,398			155,967
Operating income as a % of net sales		26.1	%		28.3	%		30.3	%		29.8	%
Depreciation and amortization		9,670			9,327			27,697			27,914
Capital expenditures		7,423			5,789			27,892			14,202

Preclinical Services
Net sales	$	112,202		$	106,108		$	326,143		$	328,680
Gross margin		27,358			22,202			76,693			79,014
Gross margin as a % of net sales		24.4	%		20.9	%		23.5	%		24.0	%
Operating income		10,975			3,663			25,958			20,844
Operating income as a % of net sales		9.8	%		3.5	%		8.0	%		6.3	%
Depreciation and amortization		10,880			11,840			32,920			36,334
Capital expenditures		2,819			2,433			5,903			7,470


Unallocated Corporate Overhead	$	(16,682	)	$	(15,103	)	$	(53,660	)	$	(44,152	)


Total
Net sales	$	278,686		$	277,579		$	849,390		$	851,685
Gross margin		93,260			92,716			301,057			301,674
Gross margin as a % of net sales		33.5	%		33.4	%		35.4	%		35.4	%
Operating income		37,682			37,094			130,696			132,659
Operating income as a % of net sales		13.5	%		13.4	%		15.4	%		15.6	%
Depreciation and amortization		20,550			21,167			60,617			64,248
Capital expenditures		10,242			8,222			33,795			21,672



CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP TO NON-GAAP
SELECTED BUSINESS SEGMENT INFORMATION (UNAUDITED) (1)
(dollars in thousands)

		Three Months Ended						Nine Months Ended
		September 29, 2012			September 24, 2011			September 29, 2012			September 24, 2011
Research Models and Services
	Net sales	$	166,484		$	171,471		$	523,247		$	523,005
	Operating income		43,389			48,534			158,398			155,967
	Operating income as a % of net sales		26.1	%		28.3	%		30.3	%		29.8	%
	Add back:
	Amortization related to acquisitions		1,611			1,586			4,542			4,992
	Severance related to cost-savings actions		934			2			934			444
	Impairment and other items (2)		2,927			(372	)		2,927			569
	Operating income, excluding specified charges (Non-GAAP)	$	48,861		$	49,750		$	166,801		$	161,972
	Non-GAAP operating income as a % of net sales		29.3	%		29.0	%		31.9	%		31.0	%

Preclinical Services
	Net sales	$	112,202		$	106,108		$	326,143		$	328,680
	Operating income		10,975			3,663			25,958			20,844
	Operating income as a % of net sales		9.8	%		3.5	%		8.0	%		6.3	%
	Add back:
	Amortization related to acquisitions		2,917			3,691			8,892			11,462
	Severance related to cost-savings actions		37			(5	)		948			979
	Impairment and other items (2)		(233	)		-			(233	)		-
	Operating losses for PCS China, PCS Massachusetts and PCS Arkansas		837			2,571			2,700			7,877
	Operating income, excluding specified charges (Non-GAAP)	$	14,533		$	9,920		$	38,265		$	41,162
	Non-GAAP operating income as a % of net sales		13.0	%		9.3	%		11.7	%		12.5	%

Unallocated Corporate Overhead		$	(16,682	)	$	(15,103	)	$	(53,660	)	$	(44,152	)
	Add back:
	Severance related to cost-savings actions		-			(72	)		-			(106	)
	Impairment and other items (2)		-			268			-			268
	Adjustment of acquisition-related contingent consideration and related items		-			-			-			(1,206	)
	Costs related to PCS China		-			265			-			406
	Costs associated with the evaluation of acquisitions		658			150			1,634			150
	Gain on settlement of life insurance policy		-			-			-			(7,710	)
	Costs associated with corporate legal entity restructuring		-			(198	)		-			785
	Convertible debt accounting (3)		53			53			160			160
	Unallocated corporate overhead, excluding specified charges (Non-GAAP)	$	(15,971	)	$	(14,637	)	$	(51,866	)	$	(51,405	)

Total
	Net sales	$	278,686		$	277,579		$	849,390		$	851,685
	Operating income		37,682			37,094			130,696			132,659
	Operating income as a % of net sales		13.5	%		13.4	%		15.4	%		15.6	%
	Add back:
	Amortization related to acquisitions		4,528			5,277			13,434			16,454
	Severance related to cost-savings actions		971			(75	)		1,882			1,317
	Adjustment of acquisition-related contingent consideration and related items		-			-			-			(1,206	)
	Impairment and other items (2)		2,694			(104	)		2,694			837
	Operating losses for PCS China, PCS Massachusetts and PCS Arkansas		837			2,836			2,700			8,283
	Costs associated with the evaluation of acquisitions		658			150			1,634			150
	Gain on settlement of life insurance policy		-			-			-			(7,710	)
	Costs associated with corporate legal entity restructuring		-			(198	)		-			785
	Convertible debt accounting (3)		53			53			160			160
	Operating income, excluding specified charges (Non-GAAP)	$	47,423		$	45,033		$	153,200		$	151,729
	Non-GAAP operating income as a % of net sales		17.0	%		16.2	%		18.0	%		17.8	%


(1)		Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2)		The three and nine months ended September 29, 2012 include items primarily related to the impairment of long-lived assets for certain RMS Europe facilities and a gain on the sale of real estate related to RMS Canada. The three months ended September 24, 2011 include a gain on the disposition of an RMS facility in Europe and costs to exit a corporate leased facility. Additionally, the nine months ended September 24, 2011 included an asset impairment associated with the Company's RMS large model operations, a gain related to the disposition of its RMS Discovery Research Services facility in Michigan, and costs associated with exiting a defined benefit plan in RMS Japan.

(3)		Includes the impact of convertible debt accounting adopted at the beginning of 2009, which increased depreciation expense.



CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF GAAP EARNINGS TO NON-GAAP EARNINGS (1)
(dollars in thousands, except for per share data)

		Three Months Ended						Nine Months Ended
		September 29, 2012			September 24, 2011			September 29, 2012			September 24, 2011

	Net income attributable to common shareholders	$	21,972		$	18,798		$	78,879		$	82,451
	Less: Discontinued operations		182			18			63			5,695
	Net income from continuing operations		22,154			18,816			78,942			88,146
	Add back:
	Amortization related to acquisitions		4,528			5,277			13,434			16,454
	Severance related to cost-savings actions		971			(75	)		1,882			1,317
	Impairment and other items (2)		2,888			(104	)		2,888			837
	Adjustment of acquisition-related contingent consideration and related items		-			-			-			(1,206	)
	Operating losses for PCS China, PCS Massachusetts and PCS Arkansas		1,025			2,836			3,044			8,283
	Costs associated with the evaluation of acquisitions		658			150			1,634			150
	Gain on settlement of life insurance policy		-			-			-			(7,710	)
	Write-off of deferred financing costs related to amended credit agreement		-			1,450			-			1,450
	Loss on sale of Auction Rate Securities		-			-			712			-
	Costs and taxes associated with corporate legal entity restructuring		-			509			-			1,492
	Convertible debt accounting, net (3)		3,860			3,496			10,928			10,216
	Tax benefit from disposition of Phase 1 clinical business		-			-			-			(11,111	)
	Tax effect		(4,886	)		(3,647	)		(11,986	)		(10,548	)
	Net income, excluding specified charges (Non-GAAP)	$	31,198		$	28,708		$	101,478		$	97,770

	Weighted average shares outstanding - Basic		47,625,806			50,084,850			48,028,602			51,671,559
	Effect of dilutive securities:
	Stock options and contingently issued restricted stock		482,808			448,897			447,544			566,868
	Weighted average shares outstanding - Diluted		48,108,614			50,533,747			48,476,146			52,238,427

	Basic earnings per share	$	0.46		$	0.38		$	1.64		$	1.60
	Diluted earnings per share	$	0.46		$	0.37		$	1.63		$	1.58

	Basic earnings per share, excluding specified charges (Non-GAAP)	$	0.66		$	0.57		$	2.11		$	1.89
	Diluted earnings per share, excluding specified charges (Non-GAAP)	$	0.65		$	0.57		$	2.09		$	1.87


(1)		Charles River management believes that supplementary non-GAAP financial measures provide useful information to allow investors to gain a meaningful understanding of our core operating results and future prospects, without the effect of one-time charges and other items which are outside our normal operations, consistent with the manner in which management measures and forecasts the Company’s performance. The supplementary non-GAAP financial measures included are not meant to be considered superior to, or a substitute for results of operations prepared in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules, regulations and guidance.

(2)		The three and nine months ended September 29, 2012 include items primarily related to the impairment of long-lived assets for certain RMS Europe facilities and a gain on the sale of real estate related to RMS Canada. The three months ended September 24, 2011 include a gain on the disposition of an RMS facility in Europe and costs to exit a corporate leased facility. Additionally, the nine months ended September 24, 2011 included an asset impairment associated with the Company's RMS large model operations, a gain related to the disposition of its RMS Discovery Research Services facility in Michigan, and costs associated with exiting a defined benefit plan in RMS Japan.

(3)		The three and nine months ended September 29, 2012 include the impact of convertible debt accounting adopted at the beginning of 2009, which increased interest expense by $3,807 and $10,768 and depreciation expense by $53 and $160, respectively. The three and nine months ended September 24, 2011 include the impact of convertible debt accounting adopted at the beginning of 2009, which increased interest expense by $3,443 and $10,056 and depreciation expense by $53 and $160, respectively.



CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
RECONCILIATION OF NET SALES GROWTH (YEAR-OVER-YEAR) EXCLUDING THE IMPACT OF FOREIGN EXCHANGE (FX) (1)
For the Three and Nine Months Ended September 29, 2012


For the three months ended September 29, 2012:	Total CRL		RMS Segment		PCS Segment

Net sales growth, reported	0.4	%	(2.9	%)	5.7	%
Impact of foreign exchange	(3.2	%)	(4.1	%)	(1.8	%)
Net sales growth, constant currency	3.6	%	1.2	%	7.5	%

For the nine months ended September 29, 2012:	Total CRL		RMS Segment		PCS Segment

Net sales growth, reported	(0.3	%)	0.0	%	(0.8	%)
Impact of foreign exchange	(2.4	%)	(2.9	%)	(1.6	%)
Net sales growth, constant currency	2.1	%	2.9	%	0.8	%

CONTACT:
Charles River Laboratories International, Inc.
Investors:
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations
susan.hardy@crl.com
or
Media:
Amy Cianciaruso, 781-222-6168
Director, Public Relations
amy.cianciaruso@crl.com

(a)	Not applicable.

(b)	Not applicable.

(c)	Exhibits.

	99.1	Press release dated October 30, 2012.

		CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Dated:	October 30, 2012

By:	/s/ Matthew L. Daniel
Matthew L. Daniel, Corporate Vice President,
Deputy General Counsel and Assistant Secretary

Exhibit No.	Description

99.1	Press release dated October 30, 2012.

2012 GUIDANCE (from continuing operations)	REVISED	PRIOR
Net sales growth, reported	Approx. (1%)	(1%) - 1%
Impact of foreign exchange	Approx. 2%	Approx. 2%
Net sales growth, constant currency	Approx. 1%	1% - 3%
GAAP EPS estimate	$2.08 - $2.13	$2.12 - $2.22
Amortization of intangible assets	$0.25	$0.25
Operating losses (1)	$0.05	$0.05
Severance costs, impairment and other items (2)	$0.10	$0.04
Convertible debt accounting	$0.20	$0.20
Non-GAAP EPS estimate	$2.68 - $2.73	$2.63 - $2.73

($ in millions)	3Q12	3Q11
Amortization of intangible assets	$4.5	$5.3
Severance related to cost-savings actions	1.0	(0.1)
Impairment and other items, net (1)	2.9	(0.1)
Operating losses for PCS China, Massachusetts and Arkansas	1.0	2.8
Costs associated with evaluation of acquisitions	0.7	0.2
Write-off of deferred financing costs related to amended credit agreement	--	1.5
Fees and tax costs associated with corporate subsidiary restructuring	--	0.5
Convertible debt accounting	3.9	3.5